39 Pages Posted: 20 Jul 2007
Date Written: July 2007
We study the relationship between regulatory regimes and pharmaceutical firms' pricing strategies using a unique policy experiment from Norway, which in 2003 introduced a reference price (RP) system called "index pricing" for a sub-sample of off-patent pharmaceuticals, replacing the existing price cap (PC) regulation. We estimate the effect of the reform using a product level panel dataset, covering the drugs exposed to RP and a large number of drugs still under PC regulation in the time before and after the policy change. Our results show that RP significantly reduces both brand-name and generic prices within the reference group, with the effect being stronger for brand-names. We also identify a negative cross-price effect on therapeutic substitutes not included in the RP-system. In terms of policy implications, the results suggest that RP is more effective than PC regulation in lowering drug prices, while the cross-price effect raises a concern about patent protection.
Keywords: pharmaceuticals, price regulation, branded-generic competition
JEL Classification: I11, L13, L51, L65
Suggested Citation: Suggested Citation
Brekke, Kurt Richard and Grasdal, Astrid and Holmas, Tor Helge, Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation? (July 2007). CESifo Working Paper No. 2059. Available at SSRN: https://ssrn.com/abstract=1001664
By Pedro Barros